EGFR+ Lung Cancer

FLAURA Trial Demonstrates Efficacy in EGFR-Positive Lung Cancer

May 06, 2020

Suresh S. Ramalingam, MD, discusses the phase III FLAURA trial.

Almonertinib Induces Response in EGFR T790M-Positive NSCLC With CNS Metastases

May 05, 2020

The study results indicated clinical efficacy against central nervous system metastases in a cohort of patients. Almonertinib also displayed an overall favorable safety profile.

Patients With EGFR Exon 20-Mutated NSCLC Demonstrate Response With Poziotinib

April 28, 2020

Interim findings of the ongoing phase II ZENITH20 trial demonstrated that poziotinib induced a 68.7% disease control rate when used as treatment of patients with pretreated non–small cell lung cancer harboring an EGFR exon 20 insertion.

Aggarwal Reviews the Latest Data Related to Systemic Therapy in Stage III NSCLC

April 19, 2020

In a Targeted Oncology case-based peer perspectives live discussion, Charu Aggarwal, MD, MPH, discussed systemic treatment options for stage III non–small cell lung cancer, based on a real case of a 63-year-old male patient.

Pembrolizumab Deemed Active Treatment for Brain Metastasis in NSCLC

April 15, 2020

Brain metastasis responses were elicited from treatment with pembrolizumab in patients with non–small cell lung cancer, in a PD-L1–positive cohort of a phase II clinical trial conducted by researchers at Yale Cancer Center. According to a YCC press release, pembrolizumab prolonged overall survival with limited toxicity in these patients.

FDA Clears IND for Novel Immunotherapy in Solid Tumors

April 15, 2020

The FDA has provided clearance to an Investigational New Drug application for GT103 for the treatment of solid tumors. A phase I clinical trial will be initiated to evaluate this novel targeted immunotherapy in patients with refractory non–small cell lung cancer, announced Grid Therapeutics, LLC.

Frontline Tislelizumab Combination Significantly Improves PFS in Nonsquamous NSCLC

April 14, 2020

The combination of tislelizumab, a PD-L1 antibody, pemetrexed and platinum-based chemotherapy achieved a statistically significant prolongation in progression-free survival compared with pemetrexed and platinum chemotherapy alone as first-line treatment of patients with nonsquamous non–small cell lung cancer, meeting the primary end point of a phase III BGB-A317-304 trial.